No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.9x · 10Y median 1.5x · 97th percentile · as of Sep 9, 2026
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-02-27. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-09-09.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-09-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-09-10T16:00:37.000Z. Latest historical point 2026-02-27. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Solventum Corporation (SOLV) stock was $88.62 as of Sep 10, 2026, 12:00 PM EDT, down 1.57% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +23.5%
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments.
Medical - Instruments & Supplies · Eagan, MN
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
56 days away
EPS Estimate
1.35
Revenue Est.
$1.93B
Last Quarter Results
EPS
$2.55
vs Estimate
$1.91
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SOLV | $15.35B | $88.62 | -1.57% | +23.52% | N/A | N/A | N/A |
| 2EXEL | $14.49B | $57.66 | -1.15% | +52.42% | +24.45% | +17.15% | vs SOLV |
| 3MEDP | $16.28B | $583.19 | -0.53% | +20.76% | +24.86% | +34.83% | vs SOLV |
| 4RVTY | $13.62B | $122.05 | -1.45% | +46.08% | -7.68% | +9.22% | vs SOLV |
| 5CRL | $13.16B | $273.28 | -1.82% | +76.93% | -8.88% | +13.46% | vs SOLV |
| 6ZBH | $17.88B | $92.41 | -2.32% | -7.95% | -6.74% | -1.67% | vs SOLV |
3.20
$2.21B
vs Estimate
$2.15B
Consensus Rating
Based on 13 analysts
Average Price Target
$93.92
+6.0% upside
Low
$70.00
Current
$88.62
High
$113.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.34 | $1.34 | $1.35 | 7 |
| Quarter ending Dec 2026 | $1.75 | $1.79 | $1.85 | 7 |
| Quarter ending Mar 2027 | $1.62 | $1.64 | $1.66 | 2 |
| Quarter ending Jun 2027 | $1.94 | $1.97 | $1.99 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $7.07 | $7.16 | $7.49 | 9 |
| FY 2027 | $6.59 | $7.30 | $7.65 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.88B | $1.93B | $2.05B | 7 |
| Quarter ending Dec 2026 | $2.08B | $2.09B | $2.10B | 7 |
| Quarter ending Mar 2027 | $2.07B | $2.08B | $2.10B | 3 |
| Quarter ending Jun 2027 | $2.25B | $2.27B | $2.29B | 3 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $8.10B | $8.24B | $8.40B | 10 |
| FY 2027 | $8.40B | $8.53B | $8.72B | 10 |
